Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trial
Related Posts
Liu H, Lee P, Vo A, Paul S, Phan QT, Lin J, Bruno VM, Stamnes MA, Moye-Rowley WS, Filler SG. The HosA histone deacetylase regulates[...]
Benzekri NA, Tin AH, Judson SD, Ripp K, Xie M, Veidis E, Barry M, Rabinowitz P. The Medicine for a Changing Planet curriculum: a mixed[...]
Gorin A, Niu S, Harriott N, Koduvayur V, Cheng QJ, Hoffmann A. IFNγ-induced memory in human macrophages is sustained by the durability of cytokine signaling[...]